Details

Autor(en) / Beteiligte

• Ponce-Ruíz, N.
• Herrera-Moreno, J. F.
• Rojas-García, A. E.
• Barrón-Vivanco, B. S.
• González-Arias, C. A.
• Bernal-Hernández, Y. Y.
• Ortega-Cervantes, L.
• Ponce-Gallegos, J.
• Hernández-Nolasco, J. A.
• Medina-Díaz, I. M.

Titel

Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population

Ist Teil von

• Heart and vessels, 2024-06, Vol.39 (6), p.563-570

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Cardiovascular diseases (CVD) are the leading cause of death globally. In recent years, follistatin-like protein 1 (FSTL1) has been proposed as an emerging potential clinical biomarker of CVD, since its concentration is upregulated in heart failure. The aim of the present study was to evaluate the association of FSTL1 levels and classic biomarkers with the risk of CVD in Mexican population. A case–control study was carried out in patients with cardiovascular diseases (CVD), arterial hypertension, but not CVD (cardiovascular risk factor—CRF), and healthy controls (control group) from the Mexican Institute of Social Security. Lipid profile, homocysteine (Hcys), serum amyloid A (SAA), FSTL1 concentration, PON1 concentration and activities [Arylesterase (ARE), and Lactonase (LAC)] were evaluated. High levels of FSTL1 were found in the CRF group and a positive association of FSTL1 (OR = 4.55; 95% CI 1.29–16.04, p  = 0.02) with the presence of arterial hypertension, as well as Hcys (OR, 3.09; 95% CI 1.23–7.76, p  = 0.02) and SAA (OR, 1.03; 95% CI 1.01–1.05, p  < 0.01) with the presence of CVD. LAC activity (OR, 0.26; 95% CI 0.07–0.94, p  = 0.04) and PON1 concentration (OR, 0.17; 95% CI 0.05–0.62, p  = 0.01) were associated with a decrease in OR belonging to the group with CVD. Our results suggest that FSTL1 may be a useful biomarker for monitoring cardiovascular risk in clinical settings. However, longitudinal studies are needed to evaluate how FSTL1 could influence the association of PON1 activity and Hcys with CVD.